Abstract
Very few drugs had a history similar to that of thalidomide (α-N-[phthalimido] gluramide). First introduced in the late 1950s in Germany, in 1961 thalidomide was withdrawn due to its teratogenic effects. More than three decades after, it is attracting growing interest because of its reported immunomodulatory and anti-inflammatory properties. The discovery that thalidomide inhibits angiogenesis led to preclinical and clinical trials as an anticancer agent in the treatment of solid tumours and haematological malignancies, as summarized in this review article. More recently, structural analogues of thalidomide have been synthesized in order to explore potential molecular targets of thalidomide, as well as to identify new agents with improved therapeutic efficacy.
| Original language | English |
|---|---|
| Pages (from-to) | 1525-1531 |
| Number of pages | 7 |
| Journal | Leukemia |
| Volume | 19 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - Sep 2005 |
Fingerprint
Keywords
- Angiogenesis
- Antiangiogenesis
- Haematological malignancies
- Thalidomide
ASJC Scopus subject areas
- Hematology
- Cancer Research
Cite this
Therapeutic renaissance of thalidomide in the treatment of haematological malignancies. / Ribatti, D.; Vacca, A.
In: Leukemia, Vol. 19, No. 9, 09.2005, p. 1525-1531.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Therapeutic renaissance of thalidomide in the treatment of haematological malignancies
AU - Ribatti, D.
AU - Vacca, A.
PY - 2005/9
Y1 - 2005/9
N2 - Very few drugs had a history similar to that of thalidomide (α-N-[phthalimido] gluramide). First introduced in the late 1950s in Germany, in 1961 thalidomide was withdrawn due to its teratogenic effects. More than three decades after, it is attracting growing interest because of its reported immunomodulatory and anti-inflammatory properties. The discovery that thalidomide inhibits angiogenesis led to preclinical and clinical trials as an anticancer agent in the treatment of solid tumours and haematological malignancies, as summarized in this review article. More recently, structural analogues of thalidomide have been synthesized in order to explore potential molecular targets of thalidomide, as well as to identify new agents with improved therapeutic efficacy.
AB - Very few drugs had a history similar to that of thalidomide (α-N-[phthalimido] gluramide). First introduced in the late 1950s in Germany, in 1961 thalidomide was withdrawn due to its teratogenic effects. More than three decades after, it is attracting growing interest because of its reported immunomodulatory and anti-inflammatory properties. The discovery that thalidomide inhibits angiogenesis led to preclinical and clinical trials as an anticancer agent in the treatment of solid tumours and haematological malignancies, as summarized in this review article. More recently, structural analogues of thalidomide have been synthesized in order to explore potential molecular targets of thalidomide, as well as to identify new agents with improved therapeutic efficacy.
KW - Angiogenesis
KW - Antiangiogenesis
KW - Haematological malignancies
KW - Thalidomide
UR - http://www.scopus.com/inward/record.url?scp=26944479753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26944479753&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2403852
DO - 10.1038/sj.leu.2403852
M3 - Article
C2 - 15973447
AN - SCOPUS:26944479753
VL - 19
SP - 1525
EP - 1531
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 9
ER -